<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>SOTRADECOL- tetradecyl hydrogen sulfate (ester) injection, solution </strong><br>Mylan Institutional LLC<br></p></div>
<h1><span class="Bold">SOTRADECOL<span class="Sup">®</span> (Sodium Tetradecyl Sulfate Injection)</span></h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8479385f-8b82-4c8e-83cb-5c5ae1302f5d"></a><a name="section-1"></a><p></p>
<p class="First"><span class="Bold">1% 20 mg/2 mL (10 mg/mL) and 3% 60 mg/2 mL (30 mg/mL)</span></p>
<p><span class="Bold">FOR INTRAVENOUS USE ONLY</span></p>
<p><span class="Bold">Rx only</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_f920732f-f715-4b74-8d44-08639394a2c3"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Sodium tetradecyl sulfate is an anionic surfactant which occurs as a white, waxy solid. The structural formula is as follows:  </p>
<div class="Figure">
<a name="id338"></a><img alt="Sodium Tetradecyl Sulfate Structural Formula " src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=f1756c28-dcd2-4b49-be62-07ca20682018&amp;name=299c3a3f-da6e-439d-872f-15f761c152d8-01.jpg">
</div>
<p>C<span class="Sub">14</span>H<span class="Sub">29</span>NaSO<span class="Sub">4</span>     7-Ethyl-2-methyl-4-hendecanol sulfate sodium salt      MW 316.44 </p>
<p>Sotradecol (sodium tetradecyl sulfate injection) is a sterile nonpyrogenic solution for intravenous use as a sclerosing agent. </p>
<p>1% 20 mg/2 mL (10 mg/mL): Each mL contains sodium tetradecyl sulfate 10 mg, benzyl alcohol 0.02 mL and dibasic sodium phosphate, anhydrous 4.0 mg in Water for Injection. pH 7.9; monobasic sodium phosphate and/or sodium hydroxide added, if needed, for pH adjustment. </p>
<p>3% 60 mg/2 mL (30 mg/mL): Each mL contains sodium tetradecyl sulfate 30 mg, benzyl alcohol 0.02 mL and dibasic sodium phosphate, anhydrous 9.0 mg in Water for Injection. pH 7.9; monobasic sodium phosphate and/or sodium hydroxide added, if needed, for pH adjustment. </p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_af78f0bc-3cad-4d72-9cb4-75cf1322f3a9"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Sotradecol (sodium tetradecyl sulfate injection) is a sclerosing agent. Intravenous injection causes intima <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> and thrombus formation. This usually occludes the injected vein. Subsequent formation of fibrous tissue results in partial or complete vein obliteration that may or may not be permanent.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_bde69f41-5f78-4ff5-9293-002b14ff1d67"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Sotradecol (sodium tetradecyl sulfate injection) is indicated in the treatment of small uncomplicated <span class="product-label-link" type="condition" conceptid="312349" conceptname="Venous varices">varicose veins</span> of the lower extremities that show simple dilation with competent valves. The benefit-to-risk ratio should be considered in selected patients who are great surgical risks. </p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_b4793212-7621-4bfb-a6cf-77908df11718"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Sotradecol (sodium tetradecyl sulfate injection) is contraindicated in previous <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> to the drug; in acute <span class="product-label-link" type="condition" conceptid="442058" conceptname="Superficial thrombophlebitis in pregnancy and the puerperium">superficial thrombophlebitis</span>; valvular or deep vein incompetence; huge superficial veins with wide open communications to deeper veins; <span class="product-label-link" type="condition" conceptid="318174" conceptname="Phlebitis">phlebitis</span> migrans; acute <span class="product-label-link" type="condition" conceptid="435613" conceptname="Cellulitis">cellulitis</span>; allergic conditions; acute <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>; varicosities caused by abdominal and pelvic tumors unless the tumor has been removed; bedridden patients; such uncontrolled systemic diseases as <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, toxic <span class="product-label-link" type="condition" conceptid="4142479" conceptname="Hyperthyroidism">hyperthyroidism</span>, <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span>, <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, neoplasm, <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span>, <span class="product-label-link" type="condition" conceptid="40528016" conceptname="Disorder of hematopoietic system">blood dyscrasias</span> and acute respiratory or skin diseases.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_id_bf6afc10-f9c8-42df-a68f-39865c28603b"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">Sotradecol (sodium tetradecyl sulfate injection) should only be administered by a healthcare professional experienced in venous anatomy and the diagnosis and treatment of conditions affecting the venous system and familiar with proper injection technique. Severe adverse local effects, including tissue <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span>, may occur following <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">extravasation</span>; therefore, extreme care in intravenous needle placement and using the minimal effective volume at each injection site are important.</p>
<p><span class="Bold">Emergency resuscitation equipment should be immediately available. <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic reactions</span>, including fatal <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, have been reported. As a precaution against <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic shock</span>, it is recommended that 0.5 mL of Sotradecol be injected into a <span class="product-label-link" type="condition" conceptid="441644" conceptname="Varicose veins of legs in pregnancy and the puerperium">varicosity</span>, followed by observation of the patient for several hours before administration of a second or larger dose. The possibility of an <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reaction</span> should be kept in mind, and the physician should be prepared to treat it appropriately.</span></p>
<p>Because of the danger of <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span> extension into the deep venous system, thorough preinjection evaluation for valvular competency should be carried out and slow injections with a small amount (not over 2 mL) of the preparation should be injected into the <span class="product-label-link" type="condition" conceptid="441644" conceptname="Varicose veins of legs in pregnancy and the puerperium">varicosity</span>. Deep venous patency must be determined by noninvasive testing such as duplex ultrasound. Venous sclerotherapy should not be undertaken if tests such as Trendelenberg and Perthes, and angiography show significant valvular or deep venous incompetence.</p>
<p>The development of <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep vein thrombosis</span> and <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span> have been reported following sclerotherapy treatment of superficial varicosities. Patients should have post-treatment follow-up of sufficient duration to assess for the development of <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep vein thrombosis</span>. <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">Embolism</span> may occur as long as four weeks after injection of sodium tetradecyl sulfate. Adequate post-treatment compression may decrease the incidence of <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep vein thrombosis</span>.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_bf05a4c8-93ca-4c27-8231-ec214672f5e4"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="i4i_precautions_general_id_d2df04bf-6df1-4fc5-83fc-b572fce8f1dc"></a><a name="section-7.1"></a><p></p>
<h2>GENERAL</h2>
<p class="First">Extreme caution must be exercised in the presence of underlying arterial disease such as marked peripheral <span class="product-label-link" type="condition" conceptid="4103842" conceptname="Arteriosclerosis">arteriosclerosis</span> or <span class="product-label-link" type="condition" conceptid="312939" conceptname="Thromboangiitis obliterans">thromboangiitis obliterans</span> (Buerger’s Disease).</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_id_c75799ae-6c54-442c-84d8-7c27c500d807"></a><a name="section-8"></a><p></p>
<h1>DRUG INTERACTIONS</h1>
<p class="First">No well-controlled studies have been performed on patients taking antiovulatory agents. The physician must use judgment and evaluate any patient taking antiovulatory drugs prior to initiating treatment with Sotradecol. (See <a href="#i4i_adverse_effects_id_c6d327ee-7ae1-440e-a7a3-3a9cd2d4a12b">ADVERSE REACTIONS</a> section.) </p>
<p>Heparin should not be included in the same syringe as Sotradecol, since the two are incompatible.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_ad1ebddf-4a7c-41b7-9361-b070b39d98f6"></a><a name="section-9"></a><p></p>
<h1>CARCINOGENESIS, MUTAGENESIS, IMPAIRMENT OF FERTILITY</h1>
<p class="First">When tested in the L5178YTK +/- mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> assay, sodium tetradecyl sulfate did not induce a dose-related increase in the frequency of thymidine kinase-deficient mutants and, therefore, was judged to be nonmutagenic in this system. However, no long-term animal carcinogenicity studies with sodium tetradecyl sulfate have been performed.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_bbae902a-9543-4a2e-a89c-cbb61f9ece8d"></a><a name="section-10"></a><p></p>
<h1>PREGNANCY</h1>
<div class="Section" data-sectionCode="34077-8">
<a name="i4i_teratogenic_id_d54dbcf9-3e7e-4586-8d27-e67493a872f0"></a><a name="section-10.1"></a><p></p>
<h2>Teratogenic Effects – Pregnancy Category C.</h2>
<p class="First">Animal reproduction studies have not been conducted with Sotradecol. It is also not known whether Sotradecol can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Sotradecol should be given to a pregnant woman only if clearly needed and the benefits outweigh the risks.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_fd23c45f-7a65-448f-8ba6-3da2b9937dfe"></a><a name="section-11"></a><p></p>
<h1>NURSING MOTHERS</h1>
<p class="First">It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Sotradecol is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_bbffe551-38e8-497f-8816-f55db8c60243"></a><a name="section-12"></a><p></p>
<h1>PEDIATRIC USE</h1>
<p class="First">Safety and effectiveness in pediatric patients have not been established. </p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_c6d327ee-7ae1-440e-a7a3-3a9cd2d4a12b"></a><a name="section-13"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">Local reactions consisting of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span> or ulceration may occur at the site of injection. A permanent discoloration may remain along the path of the sclerosed vein segment. <span class="product-label-link" type="condition" conceptid="4032013" conceptname="Desquamation">Sloughing</span> and <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span> of tissue may occur following <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">extravasation</span> of the drug. (See <a href="#i4i_warnings_id_bf6afc10-f9c8-42df-a68f-39865c28603b">WARNINGS</a> section.)</p>
<p><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic reactions</span> such as <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span>, <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, <span class="product-label-link" type="condition" conceptid="256439" conceptname="Allergic rhinitis due to pollen">hay fever</span> and <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic shock</span> have been reported. Mild systemic reactions that have been reported include <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>. (See <a href="#i4i_warnings_id_bf6afc10-f9c8-42df-a68f-39865c28603b">WARNINGS</a> section.) </p>
<p>At least six <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> have been reported with the use of Sotradecol. Four cases of <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic shock</span> leading to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> have been reported in patients who received Sotradecol. One of these four patients reported a history of <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, a contraindication to the administration of Sotradecol. (See <a href="#i4i_warnings_id_bf6afc10-f9c8-42df-a68f-39865c28603b">WARNINGS</a> section.) </p>
<p>One <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> has been reported in a patient who received Sotradecol and who had been receiving an antiovulatory agent. Another <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> (fatal <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span>) has been reported in a 36-year-old female treated with sodium tetradecyl <span class="Italics">acetate</span> and who was <span class="Bold">not</span> taking oral contraceptives.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_adc07c4d-6b5d-4c88-a6b6-005d574e2369"></a><a name="section-14"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration. Do not use if precipitated or discolored. </p>
<p>Sotradecol (sodium tetradecyl sulfate injection) is for intravenous use only. The strength of solution required depends on the size and degree of <span class="product-label-link" type="condition" conceptid="441644" conceptname="Varicose veins of legs in pregnancy and the puerperium">varicosity</span>. In general, the 1% solution will be found most useful with the 3% solution preferred for larger varicosities. <span class="Bold">The dosage should be kept small, using 0.5 mL to 2 mL (preferably 1 mL maximum) for each injection, and the maximum single treatment should not exceed 10 mL.</span></p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_edd51d16-afda-4e80-a9ae-2bc03c575178"></a><a name="section-15"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Sotradecol® (sodium tetradecyl sulfate injection) </p>
<p>NDC 67457-162-02<br>carton containing 5, 2 mL vials with 1% 20 mg/2 mL (10 mg/mL)</p>
<p>NDC 67457-163-02<br>carton containing 5, 2 mL vials with 3% 60 mg/2 mL (30 mg/mL)</p>
</div>
<div class="Section" data-sectionCode="44425-7">
<a name="i4i_storage_id_dc852f52-fc5e-4fda-acbf-b9b3230a4d2c"></a><a name="section-16"></a><p></p>
<h1>STORAGE </h1>
<p class="First"><span class="Bold">Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.]</span></p>
</div>
<div class="Section" data-sectionCode="34091-9">
<a name="i4i_animal_pharmacology_id_fb50391a-3e23-481a-935b-8fe7d175ee72"></a><a name="section-17"></a><p></p>
<h1>ANIMAL TOXICOLOGY </h1>
<p class="First">The intravenous LD<span class="Sub">50</span> of sodium tetradecyl sulfate in mice was reported to be 90 ± 5 mg/kg.</p>
<p>In the rat, the acute intravenous LD<span class="Sub">50</span> of sodium tetradecyl sulfate was estimated to be between 72 mg/kg and 108 mg/kg. </p>
<p>Purified sodium tetradecyl sulfate was found to have an LD<span class="Sub">50</span> of 2 g/kg when administered orally by stomach tube as a 25% aqueous solution to rats. In rats given 0.15 g/kg in drinking water for 30 days, no appreciable toxicity was seen, although some growth inhibition was discernible.</p>
<p>Manufactured for:<br><span class="Bold">Mylan Institutional LLC</span><br>Rockford, IL 61103 U.S.A.</p>
<p>Manufactured by:<br><span class="Bold">Mylan Institutional</span><br>Galway, Ireland</p>
<p>REVISED MARCH 2013<br>MI:SOTRIJ:R3<br>0521L108</p>
<p><span class="Sup">®</span>Sotradecol is a registered trademark of Mylan Pharma Group Limited</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_248af7d0-9f50-4c30-b928-7e7ec60cd573"></a><a name="section-18"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 10 mg/mL Carton Label</h1>
<p class="First"><span class="Bold">NDC 67457-162-02</span></p>
<p><span class="Bold">Sotradecol<span class="Sup">®</span> 1% </span><br>(sodium tetradecyl sulfate <br>injection)</p>
<p><span class="Bold">20 mg/2 mL</span><br>(10 mg/mL)</p>
<p><span class="Bold">For Intravenous Use Only</span></p>
<p><span class="Bold">Rx only     5 x 2 mL Vials</span></p>
<p><span class="Bold">Each mL contains:</span> Sodium tetradecyl sulfate 10 mg, benzyl alcohol<br>0.02 mL and dibasic sodium phosphate, anhydrous 4.0 mg in Water<br>for Injection. pH 7.9; monobasic sodium phosphate and/or sodium<br>hydroxide added, if needed, for pH adjustment.</p>
<p><span class="Bold">WARNING:</span> Do not use if precipitated.</p>
<p><span class="Bold">Usual Dosage:</span> See accompanying prescribing information.</p>
<p><span class="Bold">Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room</span><br><span class="Bold">Temperature.]</span></p>
<p>Manufactured for:<br><span class="Bold">Mylan Institutional LLC</span><br>Rockford, IL 61103 U.S.A.</p>
<p>Manufactured by:<br><span class="Bold">Mylan Institutional</span><br>Galway, Ireland</p>
<p>MI:162:5C:R3</p>
<p><span class="Bold">Mylan.com</span></p>
<div class="Figure">
<a name="id562"></a><img alt="Sotradecol 1% 10 mg/mL Carton Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=f1756c28-dcd2-4b49-be62-07ca20682018&amp;name=299c3a3f-da6e-439d-872f-15f761c152d8-02.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_84a5a830-4ea0-45cf-b6a1-86046c3cd795"></a><a name="section-19"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 30 mg/mL Carton Label</h1>
<p class="First"><span class="Bold">NDC 67457-163-02</span></p>
<p><span class="Bold">Sotradecol<span class="Sup">®</span> 3%</span><br>(sodium tetradecyl sulfate injection)</p>
<p><span class="Bold">60 mg/2 mL</span><br>(30 mg/mL)</p>
<p><span class="Bold">For Intravenous Use Only</span></p>
<p><span class="Bold">Rx only     5 x 2 mL Vials</span></p>
<p><span class="Bold">Each mL contains</span>: Sodium tetradecyl sulfate 30 mg, benzyl alcohol<br>0.02 mL and dibasic sodium phosphate, anhydrous 9.0 mg in Water<br>for Injection. pH 7.9; monobasic sodium phosphate and/or sodium<br>hydroxide added, if needed, for pH adjustment.</p>
<p><span class="Bold">WARNING:</span> Do not use if precipitated.</p>
<p><span class="Bold">Usual Dosage:</span> See accompanying prescribing information.</p>
<p><span class="Bold">Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room</span><br><span class="Bold">Temperature.]</span></p>
<p>Manufactured for:<br><span class="Bold">Mylan Institutional LLC</span><br>Rockford, IL 61103 U.S.A.</p>
<p>Manufactured by:<br><span class="Bold">Mylan Institutional</span><br>Galway, Ireland</p>
<p>MI:163:5C:R3</p>
<p><span class="Bold">Mylan.com</span></p>
<div class="Figure">
<a name="id607"></a><img alt="Sotradecol 3% 30 mg/mL Carton Labels" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=f1756c28-dcd2-4b49-be62-07ca20682018&amp;name=299c3a3f-da6e-439d-872f-15f761c152d8-03.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>SOTRADECOL 		
					</strong><br><span class="contentTableReg">tetradecyl hydrogen sulfate (ester) injection, solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:67457-162</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>TETRADECYL HYDROGEN SULFATE (ESTER)</strong> (TETRADECYL HYDROGEN SULFATE (ESTER)) </td>
<td class="formItem">TETRADECYL HYDROGEN SULFATE (ESTER)</td>
<td class="formItem">10 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Benzyl Alcohol</strong></td>
<td class="formItem">0.02 mL  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM PHOSPHATE, DIBASIC, ANHYDROUS</strong></td>
<td class="formItem">4 mg  in 1 mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Water</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:67457-162-02</td>
<td class="formItem">5  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:67457-162-00</td>
<td class="formItem">2 mL in 1 VIAL, GLASS</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA040541</td>
<td class="formItem">04/29/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>SOTRADECOL 		
					</strong><br><span class="contentTableReg">tetradecyl hydrogen sulfate (ester) injection, solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:67457-163</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>TETRADECYL HYDROGEN SULFATE (ESTER)</strong> (TETRADECYL HYDROGEN SULFATE (ESTER)) </td>
<td class="formItem">TETRADECYL HYDROGEN SULFATE (ESTER)</td>
<td class="formItem">30 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Benzyl Alcohol</strong></td>
<td class="formItem">0.02 mL  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM PHOSPHATE, DIBASIC, ANHYDROUS</strong></td>
<td class="formItem">9 mg  in 1 mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Water</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:67457-163-02</td>
<td class="formItem">5  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:67457-163-00</td>
<td class="formItem">2 mL in 1 VIAL, GLASS</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA040541</td>
<td class="formItem">04/29/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Mylan Institutional LLC
							(790384502)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 4/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>299c3a3f-da6e-439d-872f-15f761c152d8</div>
<div>Set id: f1756c28-dcd2-4b49-be62-07ca20682018</div>
<div>Version: 6</div>
<div>Effective Time: 20130429</div>
</div>
</div> <div class="DistributorName">Mylan Institutional LLC</div></p>
</body></html>
